US drug makers sue to block a federal regulation that would require them to display list prices for drugs in television advertisements; a proposal could lead to a broad settlement for opioid manufacturers that would issue a nationwide payout and prevent future lawsuits from local governments; Pfizer has agreed to buy Array BioPharma for $11.4 billion.
US drug manufacturers sued Friday to block a federal regulation from taking effect that would require them to list drug prices in television advertisements, The New York Times reported. HHS finalized the rule May 8, 2019; due to take effect in July, it represents one of the most high-profiile efforts by the Trump administration to lower prescription drug prices. Drug makers argued that list prices differ from patients' final costs, as list prices do not include rebates, discounts offered or patient assistance programs.
Pending approval by US District Judge Dan Aaron Polster, a proposal made Friday in an Ohio federal court by lawyers for hundreds of local governments could pave the way for a nationwide settlement with opioid manufacturers, according to The New York Times. The plan could expand the number of municipalities and counties eligible for compensation in federal litigation from 1650 to nearly 24,500. The proposal was suggested to provide a greater incentive for pharmaceutical companies tthat are defendants to comprehensively settle, as it would prevent future lawsuits from local governments.
In an effort to expand its presence in cancer research, Pfizer has agreed to buy Array BioPharma for $11.4 billion, paying $48 per share, The Washington Post reported. Last month, Array announced that its drugs Braftovi and Mektovi, along with another treatment, significantly improved overall survival in late-stage testing for some patients with colorectal cancer. Array planned to submit results to federal regulators later this year.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Kaiser Permanente was hit by a data breach in mid-April, impacting 13.4 million health plan members; GlaxoSmithKline (GSK) sued Pfizer and BioNTech for allegedly infringing on its messenger RNA technology patents in the companies’ COVID-19 vaccines; the CDC announced the first-known HIV cases transmitted via cosmetic injections.
Read More